2013-002730-21: The AML18 Trial is an intensive chemotherapy trial for patients over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised 1600 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy. |
|
|
| Ongoing | 3 | 1000 | Europe | AC220 (Quizartinib), Ganetespib, Mylotarg, Cladribine, STA9090, LITAK, LITAK | Cardiff University, Cancer Research UK | Acute Myeloid LeukaemiaHigh Risk Myelodysplastic Syndrome | | | | |
2014-002195-90: The AML19 Trial is an intensive chemotherapy trial for patients between 18 and 60 with AML and High Risk Myelodysplastic disease. |
|
|
| Ongoing | 3 | 2550 | Europe | Gemtuzumab ozogamicin (mylotarg), Ganetespib, CPX351- Cytarabine, CPX351-Daunorubicin, STA9090, | Cardiff University, Cancer Research UK | Acute myeloid leukaemiaHigh Risk Myelodysplastic Syndrome | | | | |
| Ongoing | 2/3 | 800 | Europe | AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Revlimid, STA9090, CHR-2797, KPT-330, EMEA/H/C/000717 -PSUV/0074, Revlimid, Revlimid | Cardiff University | Acute myeloid leukemia and high-risk myelodysplastic syndrome | | | | |
| Completed | 2 | 122 | Europe | Ganetespib, Niraparib, Carboplatin, Paclitaxel, Gemcitabine | Universitaire Ziekenhuizen KU Leuven, European Commission | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 09/23 | 09/23 | | |
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
|
|
| Recruiting | 2 | 5000 | US | Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel | QuantumLeap Healthcare Collaborative | Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer | 12/30 | 12/31 | | |